Intellia Therapeutics (NTLA) News Today $24.47 +4.03 (+19.72%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$25.08 +0.61 (+2.49%) As of 05:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Intellia Therapeutics' (NTLA) Sell (D-) Rating Reaffirmed at Weiss Ratings1 hour ago | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Trading 6.6% Higher - Here's What HappenedOctober 8 at 1:11 PM | marketbeat.comJMP Securities Upgrades Intellia Therapeutics (NASDAQ:NTLA) to Market OutperformOctober 8 at 2:57 AM | americanbankingnews.comJMP Securities Upgrades Intellia Therapeutics (NTLA)October 7 at 11:51 AM | msn.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Moderate Buy" from BrokeragesOctober 7 at 2:14 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year High Following Analyst UpgradeOctober 7 at 2:19 AM | americanbankingnews.comIntellia Therapeutics upgraded by Citizens JMP on HAE opportunity, shares rise 6%October 6 at 1:20 PM | msn.comIntellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year High on Analyst UpgradeOctober 6 at 10:18 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Citizens JmpOctober 6 at 8:52 AM | marketbeat.comIntellia upgraded to Outperform from Market Perform at Citizens JMPOctober 6 at 8:20 AM | msn.comIntellia Therapeutics (NASDAQ:NTLA) Upgraded by JMP Securities to Market Outperform RatingOctober 6 at 8:16 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) CAO Michael Dube Sells 1,871 SharesOctober 4, 2025 | insidertrades.comIntellia Therapeutics (NASDAQ:NTLA) CAO Sells $32,517.98 in StockOctober 3, 2025 | marketbeat.comIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 9.9% - Here's What HappenedOctober 1, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 99K shares of Intellia Therapeutics todayOctober 1, 2025 | msn.comBallentine Partners LLC Buys New Position in Intellia Therapeutics, Inc. $NTLAOctober 1, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 112K shares of Intellia Therapeutics todaySeptember 29, 2025 | msn.comHow Investors May Respond To Intellia Therapeutics (NTLA) Reporting Three-Year Data on Gene-Editing TherapySeptember 29, 2025 | finance.yahoo.comReassessing Intellia Therapeutics (NTLA): Valuation Insights After New Three-Year Nex-z Clinical Data and Ongoing Phase 3 ProgressSeptember 27, 2025 | finance.yahoo.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 5.9% - Here's What HappenedSeptember 26, 2025 | marketbeat.comIntellia Therapeutics announces longer-term Phase 1 data for nex-zSeptember 25, 2025 | msn.comIntellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with PolyneuropathySeptember 25, 2025 | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Shares Up 8% - What's Next?September 24, 2025 | marketbeat.comVoya Investment Management LLC Purchases 179,180 Shares of Intellia Therapeutics, Inc. $NTLASeptember 23, 2025 | marketbeat.comIntellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR ...September 22, 2025 | markets.businessinsider.comJMP Securities Reiterates "Market Perform" Rating for Intellia Therapeutics (NASDAQ:NTLA)September 20, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Expected to Rise, HC Wainwright Analyst SaysSeptember 20, 2025 | marketbeat.comIntellia Therapeutics Scores Relative Strength Rating UpgradeSeptember 20, 2025 | msn.comIntellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy ThesisSeptember 19, 2025 | seekingalpha.comIntellia Therapeutics (NASDAQ:NTLA) Sees Large Volume Increase - Time to Buy?September 19, 2025 | marketbeat.comIntellia Therapeutics Sees Unusually High Options Volume (NASDAQ:NTLA)September 19, 2025 | marketbeat.comExpert Outlook: Intellia Therapeutics Through The Eyes Of 5 AnalystsSeptember 19, 2025 | benzinga.comIntellia Therapeutics completes enrollment in Phase 3 HAELO study of Ionov-zSeptember 18, 2025 | msn.comIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Still a Buy?September 18, 2025 | marketbeat.comIntellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary AngioedemaSeptember 18, 2025 | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Shares Up 6.3% - Here's What HappenedSeptember 17, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 615.8K shares of Intellia Therapeutics todaySeptember 17, 2025 | msn.com2 More Stocks With 1,000% UpsideSeptember 14, 2025 | investorplace.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Moderate Buy" from BrokeragesSeptember 14, 2025 | marketbeat.comZacks Research Issues Positive Outlook for NTLA EarningsSeptember 12, 2025 | marketbeat.comCathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%September 11, 2025 | fool.comIntellia Therapeutics, Inc. $NTLA Shares Sold by Polar Asset Management Partners Inc.September 9, 2025 | marketbeat.comGranahan Investment Management LLC Increases Stock Position in Intellia Therapeutics, Inc. $NTLASeptember 8, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Upgraded by Wall Street Zen to "Hold" RatingSeptember 8, 2025 | marketbeat.comRussell Investments Group Ltd. Cuts Stock Position in Intellia Therapeutics, Inc. $NTLASeptember 7, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.5% - Should You Buy?September 5, 2025 | marketbeat.comPDT Partners LLC Buys 132,638 Shares of Intellia Therapeutics, Inc. $NTLASeptember 4, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 169.7K shares of Intellia Therapeutics todaySeptember 3, 2025 | msn.comArmistice Capital LLC Makes New Investment in Intellia Therapeutics, Inc. $NTLASeptember 3, 2025 | marketbeat.com Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NTLA Media Mentions By Week NTLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.740.63▲Average Medical News Sentiment NTLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼1712▲NTLA Articles Average Week Get the Latest News and Ratings for NTLA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Intellia Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Beam Therapeutics News CRISPR Therapeutics News Editas Medicine News Twist Bioscience News Revolution Medicines News Cytokinetics News Merus News Avidity Biosciences News Grifols News Abivax News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
